查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854790

按治疗领域、产品类型、分销管道和最终用户分類的女性健康治疗市场—2025-2032年全球预测

Women's Health Therapeutics Market by Therapeutic Area, Product Type, Distribution Channel, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，女性健康治疗市场将成长至 1,679.2 亿美元，复合年增长率为 11.12%。

关键市场统计数据
基准年 2024 722.1亿美元
预计年份：2025年 801.1亿美元
预测年份 2032 1679.2亿美元
复合年增长率 (%) 11.12%

为推动现代女性健康保健发展而製定的策略方向，旨在使临床创新与商业性和监管现实相一致。

本导论整理了影响当代女性健康保健的各种动态因素，并阐述了相关人员如何解读后续分析。这一领域的特点是科学创新、监管环境的变化以及对以患者为中心的医疗服务的日益重视。这些因素正在重塑临床试验设计、产品开发路径和商业化策略，而这些策略都需要跨学科思维和灵活的执行力。

本报告将治疗、产品、分销和终端用户观点整合为整体叙述，旨在为经营团队、投资者和临床领导者提供清晰易懂且实用的资讯。在各个治疗领域，临床医生和研发人员都在努力满足不同的未满足需求，而支付者和医疗服务提供者则要求提供临床和经济价值的有力证据。因此，决策者必须权衡长期的科学机会与短期的营运现实。本导言将引导读者了解这些矛盾以及贯穿整份报告的分析方法。

不断发展的科学创新、护理模式和商业变革正在重新定义女性健康领域的治疗重点和相关人员的参与方式。

科学进步、患者权益倡导和不断发展的医疗服务模式正在改变癌症治疗格局。精准肿瘤学和生物製药正在重新定义主要影响女性的癌症的治疗模式，而避孕创新和非荷尔蒙更年期疗法则响应了人们对个体化安全性和耐受性的日益重视。因此，研究重点正从广泛的人群干预转向针对特定分子亚型和患者偏好的标靶治疗。

同时，产品类型的创新正在再形成患者和医疗服务提供者可获得的产品组合。生物製药，包括单株抗体和重组蛋白，在肿瘤学和某些妇科领域日益受到重视；而涵盖诊断、监测和治疗功能的医疗器材则能够实现更早期的检测和更精准的治疗。药品仍占据核心地位，品牌药和学名药药在创新和可及性之间寻求平衡。分销管道也在不断发展，医院药房仍然是复杂治疗药物的主要供应管道，而线上药房和零售药房则正在扩大慢性病管理和避孕服务的覆盖范围。包括诊所、居家医疗、医院和专科中心在内的终端用户正在调整其工作流程，以适应分散式医疗和远端监测，这影响着产品设计和上市后支援需求。

监管路径和报销框架也在不断变化，这促使申办方儘早与监管机构和支付方接洽，设计能够展现以患者为中心的疗效和真实世界疗效的试验。整体而言，这种转变正迫使企业采用整合式开发策略，将分子科学、器材工程、监管策略和商业规划结合，以提供具有临床意义且经济可行的解决方案。

近期关税结构调整如何重塑美国医疗保健产业的供应链韧性、筹资策略与商业动态

2025年实施的新关税政策的累积影响，为在美国运营的製造商、经销商和医疗保健系统带来了多重复杂性。进口关税的变化将影响生技药品成分、原料药以及诊断和治疗设备组件的筹资策略。因此，依赖跨境供应链的公司不得不重新评估采购决策，实现供应商多元化，并在条件允许的情况下加快本地化进程，以维持供应稳定和成本可预测性。

除了投入成本外，关税波动还会影响定价策略、供应商合约和通路的经济效益。医院采购部门和专科中心正在调整库存管理方式并修订供应商合同，以减轻关税引发的成本波动的影响。同时，製造商正在评估产品设计和包装方案，以减少对受关税影响的进口产品的依赖，并深化与国内合作伙伴的合作，以维持下游供应。

重要的是，这项政策转变提升了供应链韧性的策略价值。投资于透明的供应商资讯库、关键投入品的双重采购以及敏捷的物流的企业，将更有能力应对关税波动。总之，2025 年关税政策强化了整合供应链和商业规划的必要性，这些规划应将贸易政策风险明确纳入投资组合和营运决策中。

将治疗子领域、产品架构、分销模式和最终用户需求与商业策略连结起来的详细细分主导观点

细分市场洞察揭示了不同治疗领域、产品类型、分销管道和终端用户群体中存在的差异化商业机会和营运考虑。在各个治疗领域内，乳癌、子宫颈癌、子宫内膜癌和卵巢癌等癌症的研究方向和治疗路径各不相同，使得癌症治疗更具复杂性。乳癌需要根据亚型（HER2阳性、荷尔蒙受体阳性和三阴性）采取分层治疗策略，这会影响临床开发和伴随诊断的需求。避孕方式多种多样，从屏障避孕法到植入式避孕器再到节育手术，因此产品策略必须兼顾使用者偏好、安全性以及长期依从性。子宫内膜异位症、骨盆腔发炎、卵巢症候群和子宫肌瘤等妇科疾病的诊断复杂，治疗流程多样，因此更适合采用多科诊疗模式。更年期疗法包括植物补充剂、荷尔蒙补充疗法和非荷尔蒙替代疗法，其中荷尔蒙补充疗法可进一步细分为雌激素製剂、雌激素加黄体製剂和替勃龙製剂。骨质疏鬆症的治疗包括双磷酸盐、Denosumab、副甲状腺素类似物和选择性雌激素受体调节药物，每种药物都有其独特的依从性和预防骨折的注意事项。

按产品类型划分，生物製药（包括单株抗体、重组蛋白和疫苗）在肿瘤治疗和免疫调节领域的重要性日益凸显；而涵盖诊断、监测和治疗等多种功能的医疗器械，则有助于早期发现疾病并实现个人化治疗。药品仍然至关重要，品牌药和学名药的选择在不同的医疗机构中平衡了创新与可及性之间的压力。药局、医院药局、网路药局和零售药局在确保药品供应、病患咨询和依从性支援方面各自发挥不同的作用。终端使用者细分——诊所、居家医疗、医院和专科中心——凸显了根据医疗服务提供地点调整服务模式、培训和上市后监测的必要性。总而言之，这些细分有助于制定有针对性的研发计划、差异化的打入市场策略以及精准的商业化倡议，从而将科学价值与用户需求相结合。

比较影响全球主要医疗保健区域监管策略、证据产生和准入途径的区域动态

区域洞察表明，美洲、欧洲、中东和非洲以及亚太地区在临床开发、监管互动和市场准入策略方面存在差异化的动态。在美洲，成熟的临床研究网络和一体化的医疗保健系统支持快速产生证据并促进复杂产品的上市，同时支付方越来越需要基于结果的数据来指导报销。法律规范强调严格的安全性和有效性标准，以及不断发展的途径以支持创新治疗方法。在欧洲、中东和非洲，监管的多样性和不断变化的准入基础设施需要客製化的市场进入策略。亚太地区展现出快速提升的生产能力、对生技药品和医疗设备创新不断增长的投资，以及多元化的法规环境，这些都鼓励早期开展本地合作和采用适应性强的临床试验设计。

这些区域模式表明，成功的市场进入策略需要平衡全球开发计划与特定区域的监管、报销和分销计划。与当地临床实验进行跨境合作可以缩短重点市场的证据生成时间，而与区域经销商和专业网络结盟则可以在以集中采购为主导的环境中促进更快的市场渗透。最终，了解区域运营的细微差别能够帮助申办方优先分配资源、定制证据包，并使商业化蓝图与每个区域的患者准入限制和医疗服务提供者的工作流程相匹配。

企业能力和伙伴关係策略在女性健康产品组合中脱颖而出，展现出卓越的临床执行力、供应链韧性和市场推广领导力。

公司层面的关键洞察凸显了整合能力的重要性，这种能力涵盖临床科学、供应链稳健性和商业性执行。市场领导往往将深厚的治疗专业知识与伴随诊断的投资相结合，从而实现更精准的患者分层和差异化的产品价值提案。在复杂癌症亚型和妇科小众适应症领域取得成功的公司，通常会将临床差异化与清晰的报销策略和医疗服务提供者教育计划相结合，以降低准入门槛。

卓越营运同样至关重要，那些实现供应链多元化和生产能力在地化的企业更能抵御贸易政策变化和物流中断的影响。在产品领域，投资于器械-药物组合和平台技术的企业，能够提供端到端的解决方案，进而提高病人参与，进而打造可持续的竞争优势。跨产业、学术界和医疗保健系统的策略伙伴关係能够加速证据产生和市场准入，尤其对于那些需要真实世界数据来检验疗效的治疗方法更是如此。有鑑于这些趋势，企业应投入资源加强跨职能整合，优先开发可适应不同医疗环境的模组化产品，并寻求能够提昇科学信誉和商业性影响力的合作伙伴关係。

为高阶主管提供实际的策略行动，以协调产品线、供应链和市场推广计划，加速产品推广应用，并降低营运风险。

为行业领导者提供的可操作建议着重强调了将洞察转化为竞争优势的具体步骤。首先，将研发管线重点放在具有最清晰临床差异化特征和可行证据路径的治疗领域和亚型。这意味着投资于癌症亚型的伴随诊断，或设计能够解决依从性和长期安全性问题的避孕和妇科产品。其次，透过逐步评估供应商风险、探索区域製造机会以及製定能够平抑关税成本波动的库存策略，来强化供应链。

第三，透过拓展数位化能力，提升病患教育与依从性，使商业模式适应不断变化的经销环境。第四，儘早与监管机构和支付方合作，共同製定符合疗效和真实世界结果要求的证据生成计划，从而减少产品上市初期的阻力。第五，寻求有针对性的伙伴关係，加速生技药品生产、器械整合和分散式临床试验基础设施等领域的能力建构。透过实施这些措施，产业领导者可以增强以患者为中心的创新能力，同时有效管理营运和政策相关的风险。

我们采用透明的多方法研究途径，结合专家访谈、科学证据和监管审查，以检验我们的跨学科见解。

本研究采用多方法研究策略，结合了专家访谈、同行评审的科学文献、监管指南和权威的临床实践标准，以确保可靠的依证。主要研究包括与临床医生、供应链相关人员、公司高管和政策顾问进行结构化对话，以突出新兴趋势、实际营运限制和相关人员的优先事项。这些定性研究结果与已发表的临床试验、监管文件和共识指南的二手研究结果相结合，以检验跨治疗领域和地区的专题研究发现。

为确保分析结果的准确性，本研究采用交叉验证法，对不同资料来源的洞见进行交叉检验，并经专家反覆审查。调查方法优先考虑假设的透明度，并清楚记录核心洞见的来源，使读者能够追溯结论的推导过程。必要时，研究进行了情境分析和敏感度测试，以探究政策转变和技术采纳轨迹的影响，同时始终保持事实综合与策略解读之间的清晰界线。

将治疗特异性、产品设计和营运弹性与改善患者疗效和商业性成功连结起来，从而整合策略意义。

总之，女性健康治疗领域呈现出科学创新、服务模式转变和政策动态演变交会融合的局面。治疗方法细分——包括癌症亚型、避孕技术、妇科疾病、更年期治疗、骨质疏鬆症等——需要製定量身定制的研发和商业化策略，以尊重临床细微差别和患者偏好。产品类型（生技药品、医疗器材和药品）的差异化会影响监管路径和分销选择，而终端用户和通路的多样性则要求服务模式具有适应性。

在营运层面，供应链的韧性以及与监管机构和支付方的积极互动对于确保持续的医疗服务可及性和报销至关重要。在企业层面，那些将临床差异化优势与稳健的生产实践和有针对性的伙伴关係关係相结合的公司，将更有能力将科学前景转化为持续的临床和商业性成果。最终，那些能够根据这些洞察调整其产品线、营运和打入市场策略的决策者，将更有能力在不同地区和医疗机构中实际改善女性健康。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 快速采用整合人工智慧主导的个人化荷尔蒙管理的数位疗法
  • 扩展远端医疗平台，为更年期护理提供远端监测和依从性支持
  • 增加对靶向新型分子路径的下一代非荷尔蒙避孕药的投资
  • 利用精准医疗和先进冷冻保存技术的生育力保存服务不断发展
  • 新兴的微生物组为基础的治疗方法在子宫内膜异位症和多囊性卵巢综合症症状管理中的应用
  • 结合心理健康支援和月经追踪功能的行动医疗应用程式的需求正在上升。
  • 开发一种用于持续释放骨质疏鬆药物的可植入式药物传输系统

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按治疗区域分類的女性健康治疗市场

  • 癌症治疗
    • 乳癌
      • HER2阳性
      • 荷尔蒙受体阳性
      • 三重否定
    • 子宫颈癌
    • 子宫内膜癌
    • 卵巢癌
  • 避孕药
    • 屏障法
    • 植入
    • 注射
    • 子宫内避孕器（IUD）
    • 丸
    • 避孕手术
  • 妇科疾病
    • 子宫内膜异位症
    • 骨盆腔发炎
    • 卵巢症候群
    • 子宫肌瘤
  • 更年期治疗
    • 植物补充剂
    • 荷尔蒙补充疗法
      • 雌激素
      • 雌激素+黄体素
      • 替勃龙
    • 非荷尔蒙疗法
  • 骨质疏鬆症
    • 双磷酸盐
    • Denosumab
    • Pth 类似物
    • 选择性雌激素受体调节剂

9. 女性健康治疗市场（依产品类型划分）

  • 生物製药
    • 单株抗体
    • 重组蛋白
    • 疫苗
  • 装置
    • 诊断设备
    • 监控设备
    • 治疗设备
  • 药物
    • 品牌
    • 非专利的

第十章：按分销管道分類的女性健康治疗市场

  • 药局
  • 医院药房
  • 网路药房
  • 零售药房

第十一章：按最终用户分類的女性健康治疗市场

  • 诊所
  • 居家照护
  • 医院
  • 专业中心

第十二章：各地区女性健康治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：按群体分類的女性健康治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：各国女性健康治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Bayer AG
    • Johnson & Johnson
    • Ferring BV
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Amgen Inc.
    • Novo Nordisk A/S
    • Gedeon Richter Plc
Product Code: MRR-957C47F94713

The Women's Health Therapeutics Market is projected to grow by USD 167.92 billion at a CAGR of 11.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 72.21 billion
Estimated Year [2025] USD 80.11 billion
Forecast Year [2032] USD 167.92 billion
CAGR (%) 11.12%

A strategic orientation to contemporary drivers in women's health therapeutics designed to align clinical innovation with commercial and regulatory realities

This introduction frames the contemporary dynamics shaping women's health therapeutics and sets clear expectations for how stakeholders can interpret the subsequent analysis. The landscape is characterized by scientific innovation, shifting regulatory priorities, and an intensified focus on patient-centered care. These forces are reshaping clinical trial design, product development pathways, and commercialization strategies in ways that require multidisciplinary thinking and agile execution.

The document prioritizes clarity and utility for executives, investors, and clinical leaders by synthesizing therapeutic, product, distribution, and end-user perspectives into an integrated narrative. Across therapeutic areas clinicians and developers are responding to differentiated unmet needs, while payers and providers demand robust evidence of clinical and economic value. Consequently, decision-makers must reconcile long-term scientific opportunity with near-term operational realities, and this introduction orients the reader to those tensions and the analytical approach used throughout the report.

Evolving scientific innovations, care models, and commercialization shifts that are redefining therapeutic priorities and stakeholder engagement across women's health

The therapeutic landscape is undergoing transformative shifts driven by scientific advances, patient advocacy, and evolving care delivery models. Precision oncology and biologics are redefining treatment paradigms for cancers that primarily affect women, while contraceptive innovation and nonhormonal menopausal therapies are responding to a renewed emphasis on individualized safety and tolerability. As a result, research priorities are migrating from broad population-level interventions toward targeted modalities that address molecular subtypes and patient preferences.

Concurrently, product-type innovation is reshaping the mix of offerings available to patients and providers. Biologics, including monoclonal antibodies and recombinant proteins, are becoming more prominent in oncology and certain gynecological indications, while devices that span diagnostic, monitoring, and therapeutic functions are enabling earlier detection and more precise management. Drugs remain central, with branded and generic options balancing innovation and access. Distribution channels are also evolving; hospital pharmacies continue to anchor complex therapeutics, while online and retail pharmacies expand access for chronic management and contraceptive care. End-users across clinics, homecare, hospitals, and specialty centers are adapting workflows to accommodate decentralized care and remote monitoring, thereby influencing product design and post-launch support requirements.

Regulatory pathways and reimbursement frameworks are also in flux, prompting sponsors to engage earlier with authorities and payers to design trials that demonstrate patient-centered outcomes and real-world effectiveness. Overall, these shifts compel companies to adopt integrated development strategies that connect molecular science, device engineering, regulatory strategy, and commercial planning to deliver clinically meaningful and economically viable solutions.

How recent tariff reconfigurations are reshaping supply chain resilience, sourcing strategies, and commercial dynamics across the United States healthcare sector

The cumulative impact of new tariff policies implemented in 2025 has introduced a layer of complexity for manufacturers, distributors, and health systems operating within the United States. Changes in import duties affect sourcing strategies for components of biologics, active pharmaceutical ingredients for drugs, and parts for diagnostic and therapeutic devices. Consequently, firms that rely on cross-border supply chains have had to revisit procurement decisions, diversify supplier bases, and accelerate localization where feasible to maintain stability of supply and cost predictability.

Beyond input costs, tariff changes have ripple effects across pricing strategies, contracting with providers, and the economics of channel distribution. Hospital purchasing departments and specialty centers are adjusting inventory management practices and reassessing vendor agreements to mitigate exposure to tariff-driven cost fluctuations. In parallel, manufacturers are evaluating product design and packaging options that reduce dependence on tariff-impacted imports, while also deepening collaboration with domestic partners to sustain downstream availability.

Importantly, the policy shift has elevated the strategic value of resilience in supply chains. Organizations that invest in transparent supplier mapping, dual sourcing for critical inputs, and agile logistics frameworks are positioned to manage tariff volatility more effectively. In sum, tariffs introduced in 2025 have reinforced the need for integrated supply chain and commercial planning that explicitly incorporates trade policy risk into portfolio and operational decisions.

Detailed segmentation-driven perspectives that connect therapeutic subdomains, product architectures, distribution modalities, and end-user requirements to commercial strategy

Segmentation insights reveal differentiated opportunities and operational considerations across therapeutic area, product type, distribution channel, and end-user cohorts. Within therapeutic areas, cancer therapies command nuanced attention as breast, cervical, endometrial, and ovarian cancers each present distinct research trajectories and care pathways. Breast cancer itself demands stratified approaches by HER2 positive, hormone receptor positive, and triple negative subtypes, which influence both clinical development and companion diagnostic requirements. Contraceptives encompass a wide array of options from barrier methods to implantable devices and sterilization, requiring product strategies that address user preferences, safety profiles, and long-term adherence. Gynecological disorders such as endometriosis, pelvic inflammatory disease, polycystic ovary syndrome, and uterine fibroids pose complex diagnostic challenges and variable treatment algorithms that favor multidisciplinary care models. Menopausal therapies span botanical supplements, hormone replacement therapy, and nonhormonal alternatives, with hormone replacement therapy further differentiated by estrogen, estrogen plus progestin combinations, and tibolone formulations. Osteoporosis management includes pharmacologic classes such as bisphosphonates, denosumab, parathyroid hormone analogues, and selective estrogen receptor modulators, each presenting unique adherence and fracture-prevention considerations.

From a product-type perspective, biologics-including monoclonal antibodies, recombinant proteins, and vaccines-are increasingly central in oncology and immunomodulatory indications, while devices that range from diagnostic to monitoring and therapeutic functions facilitate earlier detection and enable personalized treatment. Drugs remain vital, with branded and generic options balancing innovation and access pressures in different care settings. Distribution channels shape access dynamics; drug stores, hospital pharmacies, online pharmacies, and retail pharmacies each play distinct roles in ensuring availability, patient counseling, and adherence support. End-user segmentation across clinics, homecare, hospitals, and specialty centers underscores the necessity to tailor service models, training, and post-market surveillance according to where care is delivered. Collectively, these segmentation lenses inform targeted development plans, differentiated market-entry strategies, and precision commercialization efforts that align scientific value with user needs.

Comparative regional dynamics that influence regulatory strategy, evidence generation, and access pathways across major global healthcare regions

Regional insights point to differentiated dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence clinical development, regulatory engagement, and market entry tactics. In the Americas, established clinical research networks and integrated healthcare systems support rapid evidence generation and facilitate complex product launches, while payers increasingly demand outcomes-based data to inform reimbursement. Regulatory frameworks emphasize rigorous safety and efficacy standards alongside evolving pathways to support innovative therapies. Within Europe, Middle East & Africa, regulatory heterogeneity and variable access infrastructures require tailored market access strategies, with several markets exhibiting strong adoption of precision diagnostics and specialty centers that can accelerate uptake for niche indications. The Asia-Pacific region demonstrates rapid advancements in manufacturing capacity, increasing investment in biologics and device innovation, and varied regulatory environments that reward early local partnerships and adaptive clinical trial designs.

These regional patterns imply that successful market strategies must balance global development programs with localized regulatory, reimbursement, and distribution planning. Cross-border collaboration with local clinical investigators can shorten timelines for evidence generation in priority markets, and partnerships with regional distributors or specialty networks can facilitate faster penetration in settings where centralized procurement dominates. Ultimately, understanding regional operational nuances enables sponsors to prioritize resources, customize evidence packages, and align commercialization blueprints with patient access constraints and provider workflows in each territory.

Corporate capabilities and partnership strategies that differentiate leaders in clinical execution, supply resilience, and market adoption across women's health portfolios

Key company-level insights emphasize the importance of integrated capabilities that span clinical science, supply chain robustness, and commercial execution. Market leaders tend to combine deep therapeutic expertise with investments in companion diagnostics, enabling better patient stratification and differentiated product value propositions. Firms that have successfully navigated complex oncology subtypes or niche gynecological indications often couple clinical differentiation with clear reimbursement strategies and provider education programs that lower adoption barriers.

Operational excellence is equally critical; companies that have diversified supply chains and localized manufacturing capabilities demonstrate greater resilience to trade policy shifts and logistical disruptions. In the product arena, organizations investing in device-drug combinations or platform technologies create durable competitive moats by offering end-to-end solutions that enhance adherence and patient engagement. Strategic partnerships across industry, academia, and health systems accelerate evidence generation and market access, particularly for therapies that require real-world data to validate effectiveness. These trends suggest that companies should allocate resources to strengthen cross-functional integration, prioritize modular product development that accommodates different care settings, and pursue collaborations that amplify both scientific credibility and commercial reach.

Practical strategic actions for executives to align pipeline, supply chains, and market access plans to accelerate adoption and mitigate operational risks

Actionable recommendations for industry leaders emphasize concrete steps to convert insights into competitive advantage. First, align pipeline prioritization with therapeutic areas and subtypes that demonstrate the clearest clinical differentiators and feasible evidence pathways. This means investing in companion diagnostics for oncology subtypes and designing contraceptive and gynecological product profiles that address adherence and long-term safety concerns. Second, fortify supply chains by mapping tiered supplier risk, exploring opportunities for regional manufacturing, and building inventory strategies that smooth tariff-driven cost variability.

Third, adapt commercial models to the evolving distribution landscape by expanding digital enablement for patient education and adherence, while maintaining robust clinical engagement with hospitals and specialty centers for high-acuity therapies. Fourth, engage early with regulators and payers to co-design evidence-generation plans that meet both efficacy and real-world outcomes requirements, thereby reducing launch friction. Fifth, pursue selective partnerships that accelerate capability-building in areas such as biologics manufacturing, device integration, and decentralized trial infrastructure. By implementing these measures, industry leaders will enhance their ability to deliver patient-centered innovations while managing operational and policy-related risks effectively.

A transparent multi-method research approach combining expert interviews, scientific evidence, and regulatory review to validate insights across domains

This research leveraged a multi-method approach that brought together primary expert interviews, peer-reviewed scientific literature, regulatory guidance, and authoritative clinical practice standards to ensure a robust evidence base. Primary engagements included structured dialogues with clinicians, supply chain specialists, commercial executives, and policy advisors to surface emerging trends, real-world operational constraints, and stakeholder priorities. These qualitative inputs were synthesized with secondary research drawn from published clinical trials, regulatory filings, and consensus guidance to validate thematic findings across therapeutic areas and geographies.

Analytical rigor was maintained through cross-validation of insights across data sources and through iterative review by subject-matter experts to ensure interpretive fidelity. The methodology prioritized transparency in assumptions and clearly documented the provenance of core insights, enabling readers to trace how conclusions were derived. Where applicable, scenario analysis and sensitivity testing were used to explore implications of policy shifts and technological adoption trajectories, while maintaining clear separation between factual synthesis and strategic interpretation.

Synthesis of strategic implications that connects therapeutic specificity, product design, and operational resilience to improved patient outcomes and commercial success

In conclusion, the women's health therapeutics landscape is defined by converging opportunities in scientific innovation, shifting delivery models, and evolving policy dynamics. Therapeutic segmentation across cancer subtypes, contraceptive technologies, gynecological disorders, menopausal therapies, and osteoporosis requires tailored development and commercialization strategies that respect clinical nuance and patient preferences. Product-type differentiation between biologics, devices, and drugs influences regulatory pathways and distribution choices, while end-user and channel diversity demands adaptable service models.

Operationally, supply chain resilience and proactive engagement with regulators and payers are critical to ensuring sustained access and reimbursement. At the corporate level, firms that integrate clinical differentiation with robust manufacturing practices and targeted partnerships will be best positioned to convert scientific promise into durable clinical and commercial outcomes. Ultimately, decision-makers who align their pipelines, operations, and market-entry strategies with these insights will be better equipped to deliver meaningful improvements in women's health care across regions and care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of digital therapeutics integrating AI-driven personalized hormone management
  • 5.2. Expansion of telehealth platforms offering remote monitoring and adherence support for menopausal care
  • 5.3. Increasing investment in next-generation non-hormonal contraceptives targeting novel molecular pathways
  • 5.4. Growth of fertility preservation services leveraging precision medicine and advanced cryopreservation
  • 5.5. Emergence of microbiome-based therapies for endometriosis and PCOS symptom management
  • 5.6. Rising demand for mobile health applications combining mental health support with menstrual tracking
  • 5.7. Development of implantable drug delivery systems for sustained release of osteoporosis treatments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Women's Health Therapeutics Market, by Therapeutic Area

  • 8.1. Cancer Therapies
    • 8.1.1. Breast Cancer
      • 8.1.1.1. Her2 Positive
      • 8.1.1.2. Hormone Receptor Positive
      • 8.1.1.3. Triple Negative
    • 8.1.2. Cervical Cancer
    • 8.1.3. Endometrial Cancer
    • 8.1.4. Ovarian Cancer
  • 8.2. Contraceptives
    • 8.2.1. Barrier Methods
    • 8.2.2. Implant
    • 8.2.3. Injectable
    • 8.2.4. Iud
    • 8.2.5. Pill
    • 8.2.6. Sterilization
  • 8.3. Gynecological Disorders
    • 8.3.1. Endometriosis
    • 8.3.2. Pelvic Inflammatory Disease
    • 8.3.3. Polycystic Ovary Syndrome
    • 8.3.4. Uterine Fibroids
  • 8.4. Menopausal Therapies
    • 8.4.1. Botanical Supplements
    • 8.4.2. Hormone Replacement Therapy
      • 8.4.2.1. Estrogen
      • 8.4.2.2. Estrogen Plus Progestin
      • 8.4.2.3. Tibolone
    • 8.4.3. Nonhormonal Therapies
  • 8.5. Osteoporosis
    • 8.5.1. Bisphosphonates
    • 8.5.2. Denosumab
    • 8.5.3. Pth Analogues
    • 8.5.4. Serms

9. Women's Health Therapeutics Market, by Product Type

  • 9.1. Biologics
    • 9.1.1. Monoclonal Antibodies
    • 9.1.2. Recombinant Proteins
    • 9.1.3. Vaccines
  • 9.2. Devices
    • 9.2.1. Diagnostic Devices
    • 9.2.2. Monitoring Devices
    • 9.2.3. Therapeutic Devices
  • 9.3. Drugs
    • 9.3.1. Branded
    • 9.3.2. Generic

10. Women's Health Therapeutics Market, by Distribution Channel

  • 10.1. Drug Stores
  • 10.2. Hospital Pharmacy
  • 10.3. Online Pharmacy
  • 10.4. Retail Pharmacy

11. Women's Health Therapeutics Market, by End-User

  • 11.1. Clinics
  • 11.2. Homecare
  • 11.3. Hospitals
  • 11.4. Specialty Centers

12. Women's Health Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Women's Health Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Women's Health Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bayer AG
    • 15.3.2. Johnson & Johnson
    • 15.3.3. Ferring B.V.
    • 15.3.4. Teva Pharmaceutical Industries Ltd.
    • 15.3.5. Pfizer Inc.
    • 15.3.6. Merck & Co., Inc.
    • 15.3.7. AbbVie Inc.
    • 15.3.8. Amgen Inc.
    • 15.3.9. Novo Nordisk A/S
    • 15.3.10. Gedeon Richter Plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. WOMEN'S HEALTH THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. WOMEN'S HEALTH THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. WOMEN'S HEALTH THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CANCER THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CANCER THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CANCER THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CANCER THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CANCER THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CANCER THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CANCER THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CANCER THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HER2 POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HER2 POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HER2 POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BARRIER METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BARRIER METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BARRIER METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BARRIER METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BARRIER METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BARRIER METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IMPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IMPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IMPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IMPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IMPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IMPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY IUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STERILIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STERILIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STERILIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STERILIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STERILIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY STERILIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ENDOMETRIOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PELVIC INFLAMMATORY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PELVIC INFLAMMATORY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PELVIC INFLAMMATORY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PELVIC INFLAMMATORY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PELVIC INFLAMMATORY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PELVIC INFLAMMATORY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY UTERINE FIBROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY UTERINE FIBROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY UTERINE FIBROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY UTERINE FIBROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MENOPAUSAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MENOPAUSAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MENOPAUSAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MENOPAUSAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MENOPAUSAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MENOPAUSAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MENOPAUSAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MENOPAUSAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BOTANICAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BOTANICAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BOTANICAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BOTANICAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BOTANICAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BOTANICAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN PLUS PROGESTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN PLUS PROGESTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN PLUS PROGESTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN PLUS PROGESTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN PLUS PROGESTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY ESTROGEN PLUS PROGESTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TIBOLONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TIBOLONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TIBOLONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TIBOLONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TIBOLONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY TIBOLONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY NONHORMONAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY NONHORMONAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY NONHORMONAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY NONHORMONAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY NONHORMONAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY NONHORMONAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OSTEOPOROSIS, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OSTEOPOROSIS, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OSTEOPOROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY OSTEOPOROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DENOSUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DENOSUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DENOSUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PTH ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PTH ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PTH ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PTH ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PTH ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PTH ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY SERMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY SERMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY SERMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY SERMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY SERMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY SERMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL WOMEN'S HEALTH THERAPEUTICS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2025-2